Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer

Key facts

Sponsor

Medical Research Council

Principal Investigator

Martin E. Gore, MD

Royal Marsden NHS Foundation Trust

Intervention

aldesleukin(biological)

Enrollment

670 enrolled

Eligibility

18-81 years · All sexes

Timeline

2002 – 2006

Study locations (12)

• Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium
• Institut Jules Bordet, Brussels, Belgium
• Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium
• Universitair Ziekenhuis Antwerpen, Edegem, Belgium
• U.Z. Gasthuisberg, Leuven, Belgium
• Klinikum Kassel, Kassel, Germany
• Leiden University Medical Center, Leiden, Netherlands
• Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
• Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Netherlands
• University Medical Center Rotterdam at Erasmus Medical Center, Rotterdam, Netherlands
• Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
• National Cancer Institute - Bratislava, Bratislava, Slovakia

Collaborators

European Organisation for Research and Treatment of Cancer - EORTC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →